CN102579610B - Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof - Google Patents
Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof Download PDFInfo
- Publication number
- CN102579610B CN102579610B CN 201210095485 CN201210095485A CN102579610B CN 102579610 B CN102579610 B CN 102579610B CN 201210095485 CN201210095485 CN 201210095485 CN 201210095485 A CN201210095485 A CN 201210095485A CN 102579610 B CN102579610 B CN 102579610B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- cerebral hemorrhage
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010008111 Cerebral haemorrhage Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 59
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 17
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 17
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 19
- 241000180649 Panax notoginseng Species 0.000 claims description 19
- 241000218628 Ginkgo Species 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000237903 Hirudo Species 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 11
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 7
- 238000007598 dipping method Methods 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 2
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 229940107131 ginseng root Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 206010019468 Hemiplegia Diseases 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010018833 Haematocoele Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000005873 Hematocele Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 208000033300 perinatal asphyxia Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006145 Brain stem haemorrhage Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 206010008030 Cerebellar haemorrhage Diseases 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 208000019743 Cranial nerve injury Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010059491 Intracranial haematoma Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010058940 Putamen haemorrhage Diseases 0.000 description 1
- 208000002324 Putaminal Hemorrhage Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008918 xingnaojing Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating cerebral hemorrhage, which relates to the technical field of Chinese medicine. The composition consists of the following components in parts by weight: 8-16 parts of leech, 6-18 parts of giant knotweed, 8-16 parts of astragalus, 6-14 parts of safflower, 10-20 parts of pseudo-ginseng root, 10-20 parts of common selfheal fruit-spike, 10-20 parts of red paeony root, 6-16 parts of chaff flower root, 6-12 parts of ginkgo leaf and 6-18 parts of liquoric root. The Chinese medicinal composition for treating cerebral hemorrhage has the advantages of reasonable composition, short treatment course, high curing rate, no sequelae, safety, reliability and low price. The invention further provides a preparation method for the Chinese medicinal composition for treating cerebral hemorrhage; and the method has a simple process, and is suitable for industrial mass production.
Description
Technical field
The present invention relates to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition for the treatment of cerebral hemorrhage and preparation method thereof.
Background technology
Cerebral hemorrhage is wherein a kind of of apoplexy, and it is anxious to have onset, changes soon, causes the high characteristics of disability rate and case fatality rate, has a strong impact on patient's existence quality of life.The cause of disease of cerebral hemorrhage is a lot, can be divided into damaging and non-damage two big classes.Non-damage cerebral hemorrhage about 90% has hypertension history, in case hemorrhage, cause brain local blood circulation obstacle, cause the acute cerebral insult symptom, be common with hemiplegia, aphasia, stupor etc. how.Craniocerebral trauma causes cerebral hemorrhage at ordinary times, and the craniocerebral trauma that industrial injury, vehicle accident cause is very common, and in wartime, various weapons and abominable battlefield surroundings all might cause intracranial hemorrhage.
The cerebral hemorrhage treatment method has two kinds, and a kind of is operation, and another kind is to take medicine.Think at present, need not the hands art more during the unconscious obstacle of patient; Having obvious disturbance of consciousness, cerebral hernia still not clear is that surgical intervention obviously is better than internal medicine; Deep coma patient, double vision enlarge, vital sign is tending towards depleted person, and the medical and surgical treatment method is all undesirable.Cranium is opened in operation, exists medical expense big, and sequela is more serious, the mortality rate problem of higher, though the patient who has has kept life, Cranial nerve injury as birth trauma in various degree can appear in about 90% patient, causes to can't take care of oneself or become the plant man.When in patient's brain during hematocele 5～40 ml, adopt intravenously administrable usually, about 30% patient can cure, and about 50% patient can't cure, and about 20% the patient state of an illness on the contrary can increase the weight of, even causes death, and its curative effect is low.In addition, the patient of hematocele is by taking existing Chinese patent medicine or Western medicine etc. in the brain, and its medicine time is long, and sb.'s illness took a favorable turn slowly, and cure rate has only 10～20%, and its curative effect is low equally.
Existing internal medicine Comprehensive Treatment is with furosemide, the mannitol dehydration reduces intracranial pressure, 17-hydroxy-11-dehydrocorticosterone reduces capillary permeability, and stool adopts calcium antagonist nimodipine etc. to improve the cerebral vasospasm situation in due course, therefore, existing conventional therapy is more numerous and diverse, is easy to incur loss through delay first aid opportunity, and different degree have untoward reaction such as upper gastrointestinal hemorrhage, the infringement of kidney merit.
Traditional Chinese medicine has some unique Therapeutic Method to the cerebrovascular hemorrhage, and research has especially in recent years obtained some effects that attract people's attention, as Hirudo extract, and XINGNAOJING ZHUSHEYE etc.
Chinese patent CN100384464C discloses a kind of medicine for the treatment of cerebral hemorrhage, by 8 ~ 12 parts of Herba Melastomatis dodecandri roots, and 10 ~ 20 parts of Herba Pileae Scriptaes, 10 ~ 15 parts of Radix Acanthopanacis Trifoliatis, 6 ~ 20 parts of Radix Cirsii Japonicis, 15 ~ 25 parts of Radix Salviae Miltiorrhizaes, 10 ~ 20 parts of Radix Ilicis Pubescentiss, 20 ~ 30 parts of Ramulus Moris, 10 ~ 15 parts of Herba Leonuris, 12 ~ 20 parts of Fructus Ligustri Lucidi, 10 ~ 20 parts of Radix Achyranthis Bidentataes, Rhizoma Acori Graminei waits composition for 10 ~ 15 parts, clinical efficacy is good, but this medicine take and mostly be inconvenience, need every day the 280g Chinese crude drug to decoct, every day three times, each oral 150ml.
Chinese patent CN1254255C discloses a kind of oral liquid and compound method thereof with Hirudo treatment cerebral hemorrhage, by Hirudo: Radix Notoginseng: Radix Et Rhizoma Rhei=form at 6: 1: 2.This product has the blood circulation promoting and blood stasis dispelling function, promotes the effect of intracranial hematoma absorption; Can make the absorption of hematoma time in advance, be applicable to Acute Cerebral Hemorrhage, the treatment total effective rate reaches 95%.But this Hirudo compound oral liquid can not need to cooperate other treatment cerebral hemorrhage medicine or method together to use independently as the drug use for the treatment of cerebral hemorrhage.
Chinese invention patent CN1141121C the invention discloses a kind of medicine of cerebral hemorrhage clinical emergency treatment, and it is to be raw material with Cornu Bubali, Moschus, Radix Scutellariae, Radix Paeoniae Rubra, Radix Notoginseng, Radix Rehmanniae, is mixed with the Chinese patent medicine injection in proportion according to the different qualities of every flavor Chinese medicine.But Chinese medicine complicated component, effective ingredient it be unclear that etc., bring certain difficulty for preparation and the quality control of Chinese medicine, and the Chinese medicine injection safety problem is also more and more these years.
Summary of the invention
The object of the present invention is to provide a kind of reasonable recipe, short treating period cure rate height, do not stay Chinese medicine composition of sequela and safe and reliable cheap treatment cerebral hemorrhage and preparation method thereof.
In order to realize purpose of the present invention, Chinese medicine composition of the present invention is made by the raw material of following weight portion: Hirudo 8-16 part, Rhizoma Polygoni Cuspidati 6-18 part, Radix Astragali 8-16 part, Flos Carthami 6-14 part, Radix Notoginseng 10-20 part, Spica Prunellae 10-20 part, Radix Paeoniae Rubra 10-20 part, Radix Achyranthis Bidentatae 6-16 part, Folium Ginkgo 6-12 part, Radix Glycyrrhizae 6-18 part.
Preferably, Chinese medicine composition of the present invention is made by the raw material of following weight portion: 10 parts of Hirudos, 9 parts of Rhizoma Polygoni Cuspidati, 12 parts of the Radixs Astragali, 10 parts on Flos Carthami, 14 parts of Radix Notoginseng, 10 parts of Spica Prunellaes, 12 parts of Radix Paeoniae Rubra, 10 parts of Radix Achyranthis Bidentataes, 6 parts of Folium Ginkgos, 12 parts in Radix Glycyrrhizae.
The traditional Chinese medical science is thought, all apoplexy all are " overabundant YIN leading to insufficient YANG " syndromes that kidney-Yang declines and decreases.Cerebral hemorrhage, the symptom of " excessive YIN keeping YANG externally " yang-energy upper punch of causing exactly.The yang-energy upper punch is gathered in brain, and can not return unit.Mutual synergism can be held up its very unit between Chinese medicine composition of the present invention, takes into account the position of pathogenic factor simultaneously, has reached the effect of setting upright and uncharming.
Side of the present invention separates:
Hirudo: be the traditional extraordinary medicinal aquatic animal of China, its dry products is concocted the back traditional Chinese medical science and is used as medicine, and has effects such as treatment apoplexy, hypertension, the clear stasis of blood, amenorrhea, traumatic injury.In recent years new discovery Hirudo preparation has specially good effect at control cardiovascular and cerebrovascular disease and anticancer aspect.The effect of expansion blood capillary, microcirculation improvement, increase renal blood flow amount is arranged.The effect of its microcirculation improvement, similar with heparin, just action time is of short duration.Experiment shows: Hirudo has the effect of expansion peripheral blood vessel, blood flow increasing and minimizing vascular resistance.
Rhizoma Polygoni Cuspidati: little hardship is slightly cold.Return liver, gallbladder, lung meridian.Heat-clearing and toxic substances removing, promoting the function of the gallbladder to alleviate jaundice, expelling wind and removing dampness, dissipating blood stasis analgesic therapy, relieving cough and resolving phlegm.Be used for arthralgia, jaundice due to damp-heat, amenorrhea ， WEIJIA, cough with copious phlegm, burn due to hot liquid or fire, injury from falling down, carbuncle sore tumefacting virus.
Flos Carthami: warm in nature, acrid in the mouth.Function cures mainly promoting blood circulation to restore menstrual flow, and the silt pain relieving of loosing is used for amenorrhea, dysmenorrhea, and lochia is not all right, the lump in the abdomen mass in the abdomen, injury from falling down, skin infection swells and ache.When ancients often have what blood in vivo, often add the Flos Carthami tate.Modern pharmacology discovers that Flos Carthami has slight excited heart, reduces coronary resistance, increases the effect of coronary flow and myocardial nutrition blood flow. and Flos Carthami injection, alcohol extract, carthamin can significantly improve the hypoxia-bearing capability of mice. and Flos Carthami has protective effect to hypoxic-ischemic encephalopathy (HIE).
The Radix Astragali: nature and flavor: sweet, tepor.The Radix Astragali has benefiting QI for strengthening the superficies, arresting sweating to take off, hold in the palm the effect of skin ulcer granulation promoting, inducing diuresis to remove edema admittedly.It is weak to be used for the treatment of the deficiency of vital energy, sinking of QI of middle-JIAO, and the chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, the exterior deficiency spontaneous perspiration, carbuncle is difficult bursts, and burst for a long time and do not hold back, blood deficiency and yellow complexion, interior-heat is quenched one's thirst, chronic nephritis, albuminuria, diabetes etc.The invigorating middle warmer of Radix Astragali Preparata QI invigorating is given birth to consolidating superficial resistance holder skin ulcer.Its flavor is light, so specially reach table in edema caused by disorder of QI, so energy complement sun fills space between skin and muscles, controls impairment caused by overstrain, longue meat.The deficiency of vital energy and difficult antiperspirant person can send out, table is dredged and hyperhidrosis person can end.So its hemostasis person of collapsing the stranguria with blood, blood is from ending also with gas-solid.
Radix Notoginseng: give birth to usefulness, warm in nature, sweet in the mouth, little hardship.Gui Jing: return liver, stomach warp.Hemostasis, antithrombotic, dissipating blood stasis, detumescence, pain relieving.Has the dissipating blood stasis hemostasis, the effect of subduing swelling and relieving pain.Cure mainly: control haematemesis, hemoptysis, epistaxis, dysentery, metrorrhagia, lump in the abdomen falls and pounces on blood stasis, traumatic hemorrhage, carbuncle pain." beautiful Chinese catalpa medicine solution " cloud: " Radix Notoginseng and battalion hemostasis, the clots absorbing of promoting blood circulation, clots absorbing blood and hold back fresh blood ".
Radix Paeoniae Rubra: clots absorbing, pain relieving, removing heat from blood, detumescence.Cure mainly: control that the stasis of blood stagnates that amenorrhea, hernia abdominal mass gather, stomachache, hypochondriac pain, epistaxis, dysentery, discharging fresh blood stool, conjunctival congestion, carbuncle, injury from falling down.Radix Paeoniae Rubra: bitter in the mouth, cold nature.Return Liver Channel.Function with clearing away heat and cooling blood, eliminating stasis to stop pain.Giving birth to Radix Paeoniae Rubra wins with clearing away heat and cooling blood power.Many fever of the body for the epidemic febrile disease pathogenic heat attacking blood system in febrile diseases are hemorrhage, conjunctival congestion and swelling pain, carbuncle sore tumefacting virus.
Radix Achyranthis Bidentatae: liver; Kidney channel.Invigorating the liver and kidney; Bone and muscle strengthening; Promoting blood circulation to restore menstrual flow; Ignite (blood) descending; Inducing diuresis for treating stranguria syndrome cures mainly: soreness of waist and knee joint; Flaccidity and weakness of the lower limbs; Amenorrhea due to stagnation of blood; Dysmenorrhea; Puerperal abdominal pain due to blood stasis; Lump in the abdomen; Retention of placenta; Pyretic stranguria; Stranguria with blood; Traumatic injury; The carbuncle malignant boil; Laryngopharynx swelling and pain.
Folium Ginkgo: sweet, bitter, puckery, flat.GUIXIN, lung meridian.Astringe the lung, relieving asthma, blood circulation promoting and blood stasis dispelling, pain relieving.Be used for cough and asthma due to lung deficiency; Coronary heart disease, angina pectoris, hyperlipidemia, anticoagulant is solid.
Spica Prunellae: bitter, hot, cold.Control conjunctival congestion and swelling pain, headache.Clearing away liver-fire is controlled hypertension, hyperlipidemia, high blood viscosity and hyperglycemia.
Radix Glycyrrhizae: Radix Glycyrrhizae, sweet in the mouth, gas is flat, and is warm in nature, can rise and can fall, and positive middle-jiao yang, function of the spleen and stomach is invigorating the spleen and replenishing QI also, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.Be used for weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious pain of extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Above-mentioned Chinese medicine composition of the present invention adds various conventional adjuvant required when preparing different dosage form, for example disintegrating agent, lubricant, adhesive etc. are prepared into any oral formulations commonly used with the method for Chinese medicinal of routine, for example can be pill, capsule, tablet, powder, granule or oral liquid etc.
According to Clinical Experience, Chinese medicine composition of the present invention is preferably oral liquid.
The concrete preparation method of oral liquid of the present invention is as follows:
1) fetch water according to the above ratio trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder is broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, each 2h, and the merging ethanol extract is evaporated to 0.5g/ml (containing the crude drug amount).
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder according to the above ratio and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and be concentrated into 0.5g/ml (containing the crude drug amount).
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, stir evenly, leave standstill, filter, fill, sterilization, namely.
Advantage of the present invention is: at modern medicine screening of medicaments to the treatment of cerebral hemorrhage disease and scientifically, prescription of the present invention is collaborative mutually to have blood stasis alive, hemorrhage a, removing heat by catharsis expells the pathogenic heat only, dwindle intracerebral hematoma, reduce intracranial pressure, alleviate the effects such as recovery that cerebral edema has promoted function of nervous system.Cure mainly cerebral hemorrhage, cerebral thrombosis, and the sequela, the hemiplegia that should disease cause are particularly useful for Acute Cerebral Hemorrhage, and the curative effect height, have no side effect, and the treatment total effective rate reaches 98%, therefore the treatment cerebral hemorrhage are had extremely important meaning.
In addition, no valuable product among the present invention, used Chinese medicine source is sufficient, no in great shortage, and its preparation technology is easy to grasp, and that obeys is safe and reliable, has no side effect, and is easy to apply.
1, Chinese medicine composition animal acute toxicity test of the present invention
Medicine: the embodiment of the invention 1 prescription.
Experimental animal: 12 of regular grade NIH mices, body weight 18g ± 2g, male and female half and half.
Method and result: be divided into the blank group at random, fasting experimentized after 16 hours, and the administration group is irritated stomach by the dosage of 0.4ml/10g and given oral liquid of the present invention, presses the dosage gastric infusion of 0.4ml/10g after 5 hours more once, twice totally.Meanwhile the blank group is irritated stomach and is given consubstantiality hydrops, observes after the administration and raises seven days, and the record mouse toxicity reacts and death condition, and observes the variation of its main organs and tissue.
Conclusion: the Cmax 150g/ml(that oral liquid of the present invention can be prepared contains the crude drug amount) and the situation of maximum volume 0. 4ml/10g administration under, be administered twice to mouse stomach in one day, do not see that other toxic reaction takes place: administration after seven days mice do not have death, behavior is active, food ration is as usual, and the hair color light does not have loose dirty, and not having faints from fear has a liking for saliva, eye, mouth, nose, ear and the no abnormal secretions of crissum do not have the mashed toe of docking.Put to death mice, dissect, observe main organs such as its heart, liver, lung, kidney and organize no abnormality seen, show the oral safety of this medicine.
2, Chinese medicine composition long-term toxicity test for animals of the present invention
Medicine: the embodiment of the invention 1 prescription.
Animal: 24 of regular grade SD rats, body weight 200g ± 10g, male and female half and half are divided into 3 groups at random.
Method and result:
1) medicine preparation: divide high and low, blank three dosage groups, be respectively 150,75,0 times of clinical application amount.
2) the gastric infusion mode is adopted in experiment, all by the capacity gastric infusion of 1ml/100g, successive administration 90 days: the blank group is given the distilled water of the capacity of grade every day, every treated animal is put to death 4 then, become celestial each organs and tissues of animal is carried out perusal, and organs such as the heart, liver, spleen, lung, kidney, adrenal gland, thymus are done the pathology inspection.
Conclusion: feed during 1, each treated animal is tried, drinking-water, defecation are all normal, motion healthy active, by a hair gloss, find dead and other ANOMALOUS VARIATIONS.2, each treated animal body weight gain is normal, administration group and matched group comparison there was no significant difference (P〉0.05).3, experiment each treated animal hepatic and renal function of back and serum biochemistry measurement result and matched group compare there was no significant difference.4, experiment each treated animal hemogram checking of back and matched group compare there was no significant difference.5, each treated animal heart, liver, spleen, lung, kidney, adrenal gland, thymus outward appearance and its organ index there are no significant difference.6, each treated animal is the same with matched group, the size and form of organs such as the heart, liver, spleen, lung, kidney is normal substantially, smooth surface, no hemorrhage, adhesion or necrosis, histological examination is respectively organized internal organs and be there is no organic disease, cardiac muscle fiber does not have degeneration or necrosis, and structure is normal, and lung tissue and spleen are organized also no abnormality seen change, all no abnormal changes of structure such as hepatocyte and glomerule, renal tubules, namely relevant with drug metabolism important organ does not all have obvious change.
3, Chinese medicine composition clinical effectiveness situation of the present invention:
Choose through Cranial Computed Tomography or MRI and check cerebral hemorrhage clinical case 294 examples of making a definite diagnosis (male's 194 examples, women's 100 examples), oldest 81 years old, minimum 39 years old.Be all the patients with cerebral hemorrhage of being in hospital 1-30 days.All give Chinese medicinal composition preparation embodiment 1 oral liquid 10ml of the present invention, 3 times on the one, 14 days courses for the treatment of, the 14th day check head CT after the medication, the 28th day or carry out the scoring of nervous function damage improvement degree when leaving hospital, to observe absorption of hematoma situation and efficacy evaluation.
Clinical symptoms: in patients with cerebral hemorrhage 294 examples, can spout food stream juice gruel, panplegia paralysis 51 examples (male 38 examples, women 20 examples); Language celostomia, half body hemiplegia 121 examples (male 80 examples, women 41 examples); Can flow juice, upper limb hemiplegia 46 examples (male 32 examples, women 14 examples) for food; Can flow juice, lower limb hemiplegia 76 examples (male 44 examples, women 25 examples) for food.
In patients with cerebral hemorrhage 294 examples: putamen hemorrhage 10-30 CC 70 examples, the hemiplegia of leaning to one side; Cerebral lobar hemorrhage 30-50 CC 88 examples have headache, hemiplegia state; Pontine hemorrhage 20 ~ 30 CC 34 examples, patient's upper limb hemiplegia, facial hemiparalysis, dysphagia; Cerebellar hemorrhage 10-25CC 60 examples, patient's dysphagia, slurred speech, lower limb are inclined to one side, paralysis; Subarachnoid hemorrhage 42 examples have headache, semicoma, tic, gatism, the blind state of vision.
Criterion of therapeutical effect:
Cure: hemiplegic limb recovers 5 grades, and language performance does not have difficulty, and life can be taken care of oneself.
Produce effects: language performance is still not exclusively fluent, Myodynamia recovery 3-4 level, and life can be taken care of oneself or half self-care.
Effectively: vital sign is normal; Hemiplegic limb takes a turn for the better, Myodynamia recovery 2-3 level, and language performance is unfluent, can't take care of oneself.
Invalid: as to die from complication, clinical death.
Therapeutic outcome is analyzed
The present invention treats patients with cerebral hemorrhage 294 examples, total effective rate 98%, wherein: cure 250 examples, account for 85%; Produce effects 27 examples account for 9.2%; Effective 11 examples account for 3.8%; Invalid 6 examples account for 2%.
The specific embodiment
Below the invention will be further described for the description by the specific embodiment, but this is not to be limitation of the present invention, those skilled in the art are according to basic thought of the present invention, can make various modifications or improvement, but only otherwise break away from basic thought of the present invention, all within the scope of the present invention.
Embodiment 1: take by weighing Hirudo 10g, Rhizoma Polygoni Cuspidati 9g, Radix Astragali 12g, Flos Carthami 10g, Radix Notoginseng 14g, Spica Prunellae 10g, Radix Paeoniae Rubra 12g, Radix Achyranthis Bidentatae 10g, Folium Ginkgo 6g, Radix Glycyrrhizae 12g.
1) water intaking trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder are broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, and each 2h merges ethanol extract and is evaporated to 0.5g/ml (containing the crude drug amount).
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and be concentrated into 0.5g/ml (containing the crude drug amount).
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, stir evenly, leave standstill, filter, fill, sterilization, namely.
Embodiment 2: take by weighing Hirudo 8g, Rhizoma Polygoni Cuspidati 6g, Radix Astragali 8g, Flos Carthami 6g, Radix Notoginseng 10g, Spica Prunellae 10g, Radix Paeoniae Rubra 10g, Radix Achyranthis Bidentatae 6g, Folium Ginkgo 6g, Radix Glycyrrhizae 6g.
1) water intaking trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder are broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, and each 2h merges ethanol extract and is evaporated to 0.5g/ml (containing the crude drug amount).
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and be concentrated into 0.5g/ml (containing the crude drug amount).
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, stir evenly, leave standstill, filter, fill, sterilization, namely.
Embodiment 3: take by weighing Hirudo 16g, Rhizoma Polygoni Cuspidati 18g, Radix Astragali 16g, Flos Carthami 14g, Radix Notoginseng 20g, Spica Prunellae 20g, Radix Paeoniae Rubra 20g, Radix Achyranthis Bidentatae 16g, Folium Ginkgo 12g, Radix Glycyrrhizae 18g.
1) water intaking trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder are broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, and each 2h merges ethanol extract and is evaporated to 0.5g/ml (containing the crude drug amount).
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and be concentrated into 0.5g/ml (containing the crude drug amount).
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, stir evenly, leave standstill, filter, fill, sterilization, namely.
Embodiment 4: take by weighing Hirudo 10g, Rhizoma Polygoni Cuspidati 14g, Radix Astragali 13g, Flos Carthami 13g, Radix Notoginseng 18g, Spica Prunellae 19g, Radix Paeoniae Rubra 18g, Radix Achyranthis Bidentatae 15g, Folium Ginkgo 6g, Radix Glycyrrhizae 6g.
1) water intaking trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder are broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, and each 2h merges ethanol extract and is evaporated to 0.5g/ml (containing the crude drug amount).
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and be concentrated into 0.5g/ml (containing the crude drug amount).
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, stir evenly, leave standstill, filter, fill, sterilization, namely.
Embodiment 5: take by weighing Hirudo 16g, Rhizoma Polygoni Cuspidati 6g, Radix Astragali 8g, Flos Carthami 12g, Radix Notoginseng 18g, Spica Prunellae 16g, Radix Paeoniae Rubra 10g, Radix Achyranthis Bidentatae 12g, Folium Ginkgo 8g, Radix Glycyrrhizae 12g.
1) water intaking trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder are broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, and each 2h merges ethanol extract and is evaporated to 0.5g/ml (containing the crude drug amount).
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and be concentrated into 0.5g/ml (containing the crude drug amount).
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, add water, stir evenly, leave standstill, filter, fill, sterilization, namely.
Claims (4)
1. a Chinese medicine composition for the treatment of cerebral hemorrhage is characterized in that being made by the raw material of following weight portion: 10 parts of Hirudos, 9 parts of Rhizoma Polygoni Cuspidati, 12 parts of the Radixs Astragali, 10 parts on Flos Carthami, 14 parts of Radix Notoginseng, 10 parts of Spica Prunellaes, 12 parts of Radix Paeoniae Rubra, 10 parts of Radix Achyranthis Bidentataes, 6 parts of Folium Ginkgos, 12 parts in Radix Glycyrrhizae.
2. the Chinese medicine composition for the treatment of cerebral hemorrhage as claimed in claim 1, it is characterized in that: described Chinese medicine composition is peroral dosage form.
3. the Chinese medicine composition for the treatment of cerebral hemorrhage as claimed in claim 2, it is characterized in that: described peroral dosage form is the liquid oral dosage form.
4. the Chinese medicine composition for the treatment of cerebral hemorrhage as claimed in claim 3, it is characterized in that: described liquid oral dosage form preparation method is as follows:
1) water intaking trematodiasis, Flos Carthami, Radix Notoginseng, Spica Prunellae powder are broken into coarse powder, and with 50% alcohol dipping 2h, the back is made solvent refluxing with 10 times of amounts of coarse powder, 50% ethanol and extracted 2 times, and each 2h merges the ethanol extract concentrating under reduced pressure;
2) get Rhizoma Polygoni Cuspidati, the Radix Astragali, Radix Paeoniae Rubra, Radix Achyranthis Bidentatae, Folium Ginkgo, Radix Glycyrrhizae powder and be broken into coarse powder, add 10 times of water gagings and decocted 2 hours, filter, collect filtrate decompression and concentrate;
3) combining step 1) step 2) concentrated solution, add correctives, antiseptic, stir evenly, leave standstill, filter, fill, sterilization, namely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210095485 CN102579610B (en) | 2012-04-01 | 2012-04-01 | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210095485 CN102579610B (en) | 2012-04-01 | 2012-04-01 | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102579610A CN102579610A (en) | 2012-07-18 |
| CN102579610B true CN102579610B (en) | 2013-09-11 |
Family
ID=46469212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210095485 Active CN102579610B (en) | 2012-04-01 | 2012-04-01 | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579610B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705789B (en) * | 2014-01-14 | 2014-08-06 | 梁存福 | Pharmaceutical composition for treating cerebral hemorrhage |
| CN104306741A (en) * | 2014-09-26 | 2015-01-28 | 朱晓岩 | A traditional Chinese medicine formula for treating cerebral hemorrhage |
| CN105250765A (en) * | 2015-10-30 | 2016-01-20 | 青岛麦瑞特医药技术有限公司 | Traditional Chinese medicinal preparation for treating acute cerebral hemorrhage and preparation method of traditional Chinese medicinal preparation |
| CN105381064A (en) * | 2015-11-16 | 2016-03-09 | 宁国仙霞骨伤医院 | Traditional Chinese medicine composition for treating cerebral hemorrhage |
| CN116999501A (en) * | 2023-08-17 | 2023-11-07 | 重庆市中药研究院 | Application of astragalus-leech kidney-tonifying capsule in preparation of medicine for treating ischemic cerebrovascular diseases |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1182604A (en) * | 1996-11-20 | 1998-05-27 | 甘肃省中医院 | Ointment for treating apoplexy |
| CN1695652A (en) * | 2004-05-12 | 2005-11-16 | 陕西爱波卓科技有限责任公司 | High performance oxidation resistant compsn. extracted from plant |
| CN101884661A (en) * | 2009-05-14 | 2010-11-17 | 御盛隆堂药业有限责任公司 | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases |
| CN102048888A (en) * | 2009-10-27 | 2011-05-11 | 菲伯纳生物医药有限责任公司 | Pharmaceutical composition for eliminating thrombus |
| CN102198181A (en) * | 2011-05-24 | 2011-09-28 | 海城市中医院 | Antithrombotic and thrombosis-eliminating preparation |
| CN102228525A (en) * | 2011-06-27 | 2011-11-02 | 陈伯明 | Traditional Chinese medicine for treating cardio-cerebral vascular stagnation |
| CN102335203A (en) * | 2010-07-21 | 2012-02-01 | 张辉 | Miniature decoction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4598593B2 (en) * | 2004-05-10 | 2010-12-15 | 晶岩 韓 | Drugs for the prevention and treatment of microcirculatory disturbance caused by ischemia / reperfusion |
| JP2009013083A (en) * | 2007-07-02 | 2009-01-22 | Noriyoshi Nakao | Orally administerable composition |
| WO2010053456A1 (en) * | 2008-11-10 | 2010-05-14 | Moleac Pte. Ltd. | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
-
2012
- 2012-04-01 CN CN 201210095485 patent/CN102579610B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1182604A (en) * | 1996-11-20 | 1998-05-27 | 甘肃省中医院 | Ointment for treating apoplexy |
| CN1695652A (en) * | 2004-05-12 | 2005-11-16 | 陕西爱波卓科技有限责任公司 | High performance oxidation resistant compsn. extracted from plant |
| CN101884661A (en) * | 2009-05-14 | 2010-11-17 | 御盛隆堂药业有限责任公司 | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases |
| CN102048888A (en) * | 2009-10-27 | 2011-05-11 | 菲伯纳生物医药有限责任公司 | Pharmaceutical composition for eliminating thrombus |
| CN102335203A (en) * | 2010-07-21 | 2012-02-01 | 张辉 | Miniature decoction |
| CN102198181A (en) * | 2011-05-24 | 2011-09-28 | 海城市中医院 | Antithrombotic and thrombosis-eliminating preparation |
| CN102228525A (en) * | 2011-06-27 | 2011-11-02 | 陈伯明 | Traditional Chinese medicine for treating cardio-cerebral vascular stagnation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102579610A (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071023B (en) | Traditional Chinese medicinal composition for effectively treating diabetes | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN101869690B (en) | Method for preparing traditional Chinese medicine for treating coronary artery disease with deficiency of both qi and yin | |
| CN104524335A (en) | Pill for conditioning female endocrine disorders and preparation method of pill | |
| CN104173773A (en) | Preparation with functions of treating migraine, dispelling wind and promoting blood circulation and preparation methods | |
| CN104857366A (en) | Preoperative intervention medicine composition for neurosurgery and application thereof | |
| CN103893670A (en) | Traditional Chinese medicine pill used for treating cardia-cerebrovascular diseases | |
| CN102886019A (en) | Traditional Chinese medicinal blood sugar reducing plaster | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN103110911B (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN105727001A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN104117020A (en) | Traditional Chinese medicinal formula for treating atrial fibrillation | |
| CN104740078A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN106266427A (en) | A kind of Traditional Chinese medicinal liquor treating nephropathy and preparation method thereof | |
| CN106389821A (en) | Traditional Chinese medicine preparation for treatment of blood transfusion hemolytic reaction and preparation method thereof | |
| CN104758888A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104027528A (en) | Traditional Chinese medicine pill for treating nephritis | |
| CN103386083B (en) | A kind of pharmaceutical composition for the treatment of type ii diabetes | |
| CN105853851A (en) | Powder for treating heart failure by warming yang and tonifying qi | |
| CN103356970A (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia | |
| CN104306943A (en) | Traditional Chinese medicine combination for curing hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI WEILI Free format text: FORMER OWNER: XU CONGYU Effective date: 20130326 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130326 Address after: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Applicant after: Li Weili Address before: 276017 A302 building, Linyi hi tech Industrial Development Zone, Shandong, China Applicant before: Xu Congyu |
|
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Xiangping Inventor before: Liu Huantai |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU HUANTAI TO: LI XIANGPING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG SANJIANG CONSTRUCTION MACHINERY CO., LTD. Free format text: FORMER OWNER: LI WEILI Effective date: 20140725 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140725 Address after: 226200 Nanhai Road, Binhai Industrial Park, Nantong, Jiangsu, Qidong Patentee after: Qidong Sanjiang Construction Machinery Co., Ltd. Address before: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Patentee before: Li Weili |